BALA CYNWYD, Pa., Nov. 12, 2013 /PRNewswire/ -- Law office of
Brodsky & Smith, LLC announces that it is investigating
potential claims against the Board of Directors of ViroPharma, Inc.
("ViroPharma" or the "Company") (Nasdaq -VPHM -News) relating to
the proposed acquisition by Shire PLC. ("Shire").
Click here to learn more about the investigation
http://brodsky-smith.com/675-vphm-viropharma-inc.html, or call
877-534-2590. There is no cost or obligation to you.
Under the terms of the transaction, ViroPharma shareholders will
receive only $50.00 in cash for each
share of ViroPharma stock they own. The investigation concerns
possible breaches of fiduciary duty and other violations of state
law by the Board of Directors of ViroPharma for not acting in the
Company's shareholders' best interests in connection with the sale
process. The investigation seeks to determine if the ViroPharma
Board of Directors failed to conduct an adequate auction process
and as a result harmed the ViroPharma shareholders by undervaluing
their Company.
If you own shares of ViroPharma common stock and wish to discuss
the legal ramifications of the proposed transaction, or have any
questions, you may e-mail or call the law office of Brodsky &
Smith, LLC who will, without obligation or cost to you, attempt to
answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith,
LLC, Two Bala Plaza, Suite 602, Bala
Cynwyd, PA 19004, by e-mail at
investorrelations@brodsky-smith.com, by visiting
http://brodsky-smith.com/675-vphm-viropharma-inc.html, or calling
toll free 877-LEGAL-90.
Brodsky & Smith, LLC is a litigation law firm with extensive
expertise representing shareholders throughout the nation in
securities and case action lawsuits. The attorneys at Brodsky &
Smith have been appointed by numerous courts throughout the country
to serve as lead counsel in class actions and successfully
recovered millions of dollars for our clients and shareholders.
Attorney advertising. Prior results do not guarantee a similar
outcome.
SOURCE Brodsky & Smith, LLC